Yoh Takekuma
About
Yoh Takekuma is a scholar working on Oncology, Surgery and Pharmacology.
According to data from OpenAlex, Yoh Takekuma has authored 156 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 30 papers in Surgery and 21 papers in Pharmacology. Recurrent topics in Yoh Takekuma's work include Antibiotics Pharmacokinetics and Efficacy (17 papers), Cancer Treatment and Pharmacology (14 papers) and Antimicrobial Resistance in Staphylococcus (13 papers). Yoh Takekuma is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (17 papers), Cancer Treatment and Pharmacology (14 papers) and Antimicrobial Resistance in Staphylococcus (13 papers). Yoh Takekuma collaborates with scholars based in Japan, United States and New Zealand. Yoh Takekuma's co-authors include Mitsuru Sugawara, Katsumi Miyazaki, Yuki Sato, Shungo Imai, Hitoshi Kashiwagi, Takayuki Miyai, Yoshitaka Saito, Ken Iseki, Xin He and Yukinaga Kishikawa and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.
In The Last Decade
Yoh Takekuma
135 papers receiving 1.2k citations
Peers
Yoh Takekuma
Jianghong Fan United States
Mingkang Zhong China
Matthew Wright United States
Rick Greupink Netherlands
Pradeep Sharma United Kingdom
Tony K. L. Kiang Canada
Oxana Doroshyenko Germany
Thomas Kerbusch Netherlands
Akihiro Hisaka Japan
Thomas C. Dowling United States
Citations per year, relative to Yoh Takekuma Yoh Takekuma (= 1×)
peers
Jianghong Fan
Countries citing papers authored by Yoh Takekuma
Since
Specialization
Citations
This map shows the geographic impact of Yoh Takekuma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoh Takekuma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoh Takekuma more than expected).
Fields of papers citing papers by Yoh Takekuma
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yoh Takekuma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoh Takekuma. The network helps show where Yoh Takekuma may publish in the future.
Co-authorship network of co-authors of Yoh Takekuma
This figure shows the co-authorship network connecting the top 25 collaborators of Yoh Takekuma. A scholar is included among the top collaborators of Yoh Takekuma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoh Takekuma. Yoh Takekuma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Narumi, Katsuya, Yoshitaka Saito, Ayako Furugen, et al.. (2025). Validity and Utility of a Risk Prediction Model for Wound Infection After Lower Third Molar Surgery. Oral Diseases. 31(6). 1922–1931.
2.
Yamaguchi, Atsushi, Yoshitaka Saito, Keisuke Okamoto, et al.. (2024). Association Between Multisystem Immune-related Adverse Events and Progression-free Survivals in PD-1/PD-L1 Inhibitor Monotherapy. In Vivo. 38(6). 2886–2896.
3.
Saito, Yoshitaka, Yoh Takekuma, Yoshito Komatsu, & Mitsuru Sugawara. (2024). Impact of preexisting proteinuria on the development of regorafenib-induced problematic proteinuria in real-world metastatic colorectal cancer treatment. Scientific Reports. 14(1). 5153–5153.
4.
Furugen, Ayako, Ayako Nishimura, Takeshi Umazume, et al.. (2024). Validated UPLC-MS/MS method for quantification of melatonin receptor agonists and dual orexin receptor antagonists in human plasma and breast milk: Application to quantify suvorexant and lemborexant in clinical samples. Journal of Pharmaceutical and Biomedical Analysis. 251. 116432–116432.
5.
Kubota, Atsuhito, Shungo Imai, Masaru Terasaki, et al.. (2024). Immunoregulatory Effects of Elemental Diet and Its Ingredient, Tryptophan, via Activation of the Aryl Hydrocarbon Receptor in Mice. International Journal of Molecular Sciences. 25(6). 3448–3448.
6.
Mori, Ayako, Izumi Kato, Katsuya Narumi, et al.. (2023). Quantitative analysis of communication changes in online medication counseling using the Roter Interaction System. Research in Social and Administrative Pharmacy. 20(1). 36–42.
7.
Ishiguro, Nobuhisa, Sumio Iwasaki, Keisuke Taki, et al.. (2023). Correlation between antibiotic use and resistance of gram-negative bacteria at a university hospital in Japan from 2013 to 2021: a study using the Japan Surveillance for Infection Prevention and Healthcare Epidemiology (J-SIPHE) system. European Journal of Hospital Pharmacy. 32(1). 3–9.
8.
Hayakawa, Mineji, et al.. (2023). Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness. Journal of Clinical Medicine. 12(3). 860–860.
9.
Narumi, Katsuya, Yoshitaka Saito, Ayako Furugen, et al.. (2022). Evaluation of the strategies to reduce third‐generation oral cephalosporins in dentistry at a Japanese academic hospital: An interrupted time series analysis. Journal of Clinical Pharmacy and Therapeutics. 47(7). 1010–1019.
10.
Miyamoto, Yasushi, et al.. (2022). Hepatic drug metabolism in older people with body composition changes. Geriatrics and gerontology international. 22(5). 449–454.
11.
Imai, Shungo, Takayuki Miyai, Hitoshi Kashiwagi, et al.. (2022). Using Japanese big data to investigate novel factors and their high‐risk combinations that affect vancomycin‐induced nephrotoxicity. British Journal of Clinical Pharmacology. 88(7). 3241–3255.
12.
Ishiguro, Nobuhisa, Takehiro Yamada, Sumio Iwasaki, et al.. (2021). Clinical outcomes of intervention for carbapenems and anti-methicillin-resistant Staphylococcus aureus antibiotics by an antimicrobial stewardship team. American Journal of Infection Control. 49(12). 1493–1498.
13.
Imai, Shungo, et al.. (2021). Clinical applicability of urinary creatinine clearance for determining the initial dose of vancomycin in critically ill patients. Journal of Infection and Chemotherapy. 28(2). 199–205.
14.
Imai, Shungo, Kenji Momo, Hitoshi Kashiwagi, et al.. (2021). A cross-sectional survey of hospitalization and blood tests implementation status in patients who received tolvaptan under 75 years of age using a Japanese claims database. Expert Opinion on Drug Safety. 20(10). 1257–1266.
15.
Imai, Shungo, Hitoshi Kashiwagi, Yuki Sato, et al.. (2021). Factors affecting creatine phosphokinase elevation during daptomycin therapy using a combination of machine learning and conventional methods. British Journal of Clinical Pharmacology. 88(3). 1211–1222.
16.
Imai, Shungo, Kenji Momo, Hitoshi Kashiwagi, et al.. (2020). Nonsteroidal anti‐inflammatory drugs use in patients with chronic kidney disease are often prescribed from different clinicians than those who diagnosed them. Pharmacoepidemiology and Drug Safety. 29(8). 873–880.
17.
Imai, Shungo, Kenji Momo, Hitoshi Kashiwagi, et al.. (2020). Comparison of interactions between warfarin and cephalosporins with and without the N-methyl-thio-tetrazole side chain. Journal of Infection and Chemotherapy. 26(11). 1224–1228.
18.
Ishiguro, Nobuhisa, Takehiro Yamada, Sumio Iwasaki, et al.. (2020). Efficacy and safety of colistin for the treatment of infections caused by multidrug-resistant gram-negative bacilli. Journal of Infection and Chemotherapy. 27(3). 473–479.
19.
Imai, Shungo, Yoh Takekuma, Hitoshi Kashiwagi, et al.. (2020). Validation of the usefulness of artificial neural networks for risk prediction of adverse drug reactions used for individual patients in clinical practice. PLoS ONE. 15(7). e0236789–e0236789.
20.
Takekuma, Yoh, Toru Takenaka, Hiroshi Okamoto, et al.. (2006). Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol.. PubMed. 9(1). 101–12.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jianghong Fan Breakdown of academic impact, for papers by Mingkang Zhong Breakdown of academic impact, for papers by Matthew Wright Breakdown of academic impact, for papers by Rick Greupink Breakdown of academic impact, for papers by Pradeep Sharma Breakdown of academic impact, for papers by Tony K. L. Kiang Breakdown of academic impact, for papers by Oxana Doroshyenko Breakdown of academic impact, for papers by Thomas Kerbusch Breakdown of academic impact, for papers by Akihiro Hisaka Breakdown of academic impact, for papers by Thomas C. Dowling